# Citations Needed

This document tracks all claims in the educational content that require scientific citations or references.

---

## High Priority: Clinical/Scientific Claims

### Core Module

#### `modules/core/02-accuracy.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| 17-23 | DEXA precision CV%: Total body fat 1-2%, Lean mass 0.5-1%, BMD 1-1.5%, VAT 2-4% | Validation study or manufacturer data | DONE |
| 53-58 | Method comparison: DEXA +/-1-2%, BIA +/-4-8%, Skinfolds +/-3-5% | Comparative study/meta-analysis | DONE |
| 64-72 | DEXA validated against 4-compartment models, MRI, CT | Review article | DONE |

**Citations added:**
- Shepherd JA, et al. "Body composition by DXA." Bone. 2017;104:101-105.
- Toombs RJ, et al. "The impact of recent technological advances on the trueness and precision of DXA." Obesity. 2012;20(1):30-39.
- Achamrah N, et al. "Comparison of body composition assessment by DXA and BIA." PLoS One. 2018;13(7):e0200465.
- Kaul S, et al. "Dual-energy X-ray absorptiometry for quantification of visceral fat." Obesity. 2012;20(6):1313-1318.

#### `modules/core/03-key-metrics.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | Body fat percentage reference ranges (essential, athletes, fitness, acceptable, obese) | ACSM guidelines or population studies | DONE |
| -- | VAT risk thresholds: <100 cm2 normal, 100-160 cm2 elevated, >160 cm2 high | Consensus statement or epidemiological study | DONE |
| -- | Android/gynoid ratio interpretation | Clinical guidelines | DONE |

**Citations added:**
- ACSM's Guidelines for Exercise Testing and Prescription. 11th ed. 2022.
- Neeland IJ, et al. "Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease." Lancet Diabetes Endocrinol. 2019;7(9):715-725.
- Kaul S, et al. Obesity. 2012.
- Bennett KA, et al. "Evaluation of visceral adipose tissue thresholds." Obes Rev. 2024;25(8):e13767.

#### `modules/core/05-misconceptions.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | DEXA radiation dose comparison (chest X-ray, cross-country flight) | Radiation safety guidelines | DONE |
| -- | Scanning frequency safety | Manufacturer/regulatory guidance | DONE |
| -- | Body recomposition feasibility | Research reviews | DONE |

**Citations added:**
- IAEA radiation protection guidance for DXA
- Barakat C, et al. "Body Recomposition." Strength Cond J. 2020;42(5):7-21.

---

### Physician Module

#### `modules/physician/01-clinical-indications.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| 21 | "VAT is an independent predictor of metabolic disease risk" | Prospective cohort studies | DONE |
| -- | GLP-1 body composition monitoring | Clinical trial data | DONE |

**Citations added:**
- Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019.
- Wilding JPH, et al. STEP 1 body composition substudy. J Endocr Soc. 2021.

#### `modules/physician/02-interpreting-results.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | EWGSOP2 sarcopenia diagnostic criteria | EWGSOP2 consensus paper | DONE |
| -- | Lean mass changes by decade of life | Longitudinal studies | DONE |

**Citations added:**
- Cruz-Jentoft AJ, et al. "Sarcopenia: revised European consensus." Age Ageing. 2019;48(1):16-31.
- Volpi E, et al. "Muscle tissue changes with aging." Curr Opin Clin Nutr Metab Care. 2004;7(4):405-410.
- Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019.

#### `modules/physician/04-red-flags.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | VAT >200 cm2 as severely elevated threshold | Clinical guidelines | DONE |
| -- | >5% muscle loss in 3-6 months as concerning | Sarcopenia literature | DONE |
| -- | >15% limb asymmetry as clinically significant | Rehabilitation/PT literature | DONE |
| -- | Cachexia diagnostic criteria | ESPEN/consensus definitions | DONE |

**Citations added:**
- Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019.
- Cruz-Jentoft AJ, et al. Age Ageing. 2019.
- ISCD Position on Body Composition Analysis Reporting. J Clin Densitom. 2013.
- Fearon K, et al. "Definition and classification of cancer cachexia." Lancet Oncol. 2011;12(5):489-495.

---

### Deep Dives

#### `deep-dives/sarcopenia/01-sarcopenia-aging.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| 26-29 | ALM/height2 cut-points: Men <7.0, Women <5.5 kg/m2 | EWGSOP2 | DONE |
| 39-41 | Sarcopenia prevalence: 5-13% (60-70y), 11-50% (70-80y), 50%+ (80+) | Systematic review | DONE |
| 56 | Sarcopenia ICD-10 code M62.84 | ICD-10-CM | DONE |
| 75 | Muscle loss rate: 3-8% per decade after 30 | Longitudinal studies | DONE |
| 113-116 | Protein requirements: 1.0-1.2 g/kg minimum, 1.2-1.6 g/kg optimal | PROT-AGE, ESPEN | DONE |

**Citations added:**
- Cruz-Jentoft AJ, et al. EWGSOP2. Age Ageing. 2019.
- Petermann-Rocha F, et al. "Global prevalence of sarcopenia." J Cachexia Sarcopenia Muscle. 2022;13(1):86-99.
- Anker SD, et al. "Welcome to the ICD-10 code for sarcopenia." J Cachexia Sarcopenia Muscle. 2016;7(5):512-514.
- Mitchell WK, et al. "Sarcopenia, dynapenia, and the impact of advancing age." Front Physiol. 2012;3:260.
- Bauer J, et al. PROT-AGE position paper. JAMDA. 2013;14(8):542-559.
- Deutz NE, et al. ESPEN Expert Group. Clin Nutr. 2014;33(6):929-936.

#### `deep-dives/visceral-fat/01-understanding-vat.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | VAT inflammatory markers and metabolic activity | Research reviews | DONE |
| -- | DEXA VAT validation against CT | Validation study | DONE |
| -- | VAT threshold values | Clinical guidelines | DONE |
| -- | VAT and disease outcomes | Prospective studies | DONE |

**Citations added:**
- Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019.
- Kaul S, et al. Obesity. 2012.
- Bennett KA, et al. Obes Rev. 2024.

#### `deep-dives/visceral-fat/02-intervention-tracking.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | Exercise VAT reduction meta-analysis | Meta-analysis | DONE |
| -- | GLP-1 VAT effects | Clinical trials | DONE |
| -- | Diet intervention outcomes | Research reviews | DONE |
| -- | Intervention effect sizes | Multiple sources | DONE |

**Citations added:**
- Vissers D, et al. "Effect of exercise on visceral adipose tissue." PLoS One. 2013;8(2):e56415.
- Wilding JPH, et al. STEP 1. Diabetes Obes Metab. 2022.
- Look M, et al. SURMOUNT-1. Diabetes Obes Metab. 2025.
- Neeland IJ, et al. Lancet Diabetes Endocrinol. 2019.

#### `deep-dives/glp1-monitoring/01-tracking-weight-loss.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | STEP 1 body composition data | Clinical trial | DONE |
| -- | SURMOUNT-1 body composition data | Clinical trial | DONE |

**Citations added:**
- Wilding JPH, et al. STEP 1. Diabetes Obes Metab. 2022.
- Look M, et al. SURMOUNT-1. Diabetes Obes Metab. 2025.
- Cruz-Jentoft AJ, et al. EWGSOP2. Age Ageing. 2019.

#### `deep-dives/glp1-monitoring/02-preserving-muscle.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | Protein needs during pharmacological weight loss | Position papers | DONE |
| -- | Resistance training preservation effects | Research reviews | DONE |

**Citations added:**
- Bauer J, et al. PROT-AGE. JAMDA. 2013.
- Jager R, et al. ISSN Position Stand. JISSN. 2017.
- Deutz NE, et al. ESPEN Expert Group. Clin Nutr. 2014.
- Cruz-Jentoft AJ, et al. EWGSOP2. Age Ageing. 2019.

#### `deep-dives/bone-health/01-bone-density-basics.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | USPSTF osteoporosis screening guidelines | USPSTF recommendation | DONE |

**Citations added:**
- USPSTF. "Screening for Osteoporosis to Prevent Fractures." JAMA. 2025.
- ISCD. "2023 Official Positions--Adult."
- Shepherd JA, et al. Bone. 2017.

---

## Medium Priority: Best Practice Claims

### Trainer Module

#### `modules/trainer/01-program-design.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | Protein targets for muscle building | ISSN position stand | DONE |
| -- | Body recomposition feasibility by training status | Research reviews | DONE |

**Citations added:**
- Jager R, et al. ISSN Position Stand. JISSN. 2017.
- Barakat C, et al. "Body Recomposition." Strength Cond J. 2020.

**Accuracy correction:** Protein target for muscle building updated from "1.6-2.2 g/kg" to "1.4-2.0 g/kg" per ISSN position stand. Higher range (2.3-3.1 g/kg) noted for hypocaloric periods.

#### `modules/trainer/03-tracking-cadence.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | Recommended scan intervals (3-6 months) | Expert consensus/precision data | DONE |
| -- | Minimum detectable change thresholds | DEXA precision studies | DONE |

**Citations added:**
- Shepherd JA, et al. Bone. 2017.
- Toombs RJ, et al. Obesity. 2012.

### Chiropractor Module

#### `modules/chiropractor/01-msk-relevance.md`

| Line | Claim | Citation Type | Status |
|------|-------|---------------|--------|
| -- | 4:1 knee force multiplier per pound of body weight | Biomechanics research | DONE |

**Citations added:**
- Messier SP, et al. "Weight loss reduces knee-joint loads." Arthritis Rheum. 2005;52(7):2026-2032.

---

## Citation Format

Citations use markdown footnote format:

```markdown
Studies show DEXA precision for body fat percentage is typically 1-2% CV.[^1]

[^1]: Shepherd JA, et al. "Body composition by DXA." Bone. 2017;104:101-105.
```

Or inline references:

```markdown
According to the EWGSOP2 consensus (Cruz-Jentoft et al., 2019), sarcopenia is defined as...
```

---

## Status Key

- DONE - Citation added to content
- TODO - Citation still needed

---

## Accuracy Flags

During citation research, the following claim was found to be inaccurate and has been corrected:

1. **`modules/trainer/01-program-design.md`**: Protein target was listed as "1.6-2.2 g/kg" for muscle building. The ISSN position stand (Jager et al., 2017) actually recommends 1.4-2.0 g/kg/day. The content has been corrected. Higher intakes (2.3-3.1 g/kg/day) are recommended during hypocaloric periods to maximize lean mass retention.

2. **`deep-dives/glp1-monitoring/01-tracking-weight-loss.md`**: The SURMOUNT-1 lean mass component was listed as "~33% of total loss" in the original content. The actual DEXA substudy data (Look et al., 2025) shows approximately 25% lean mass / 75% fat mass across all tirzepatide doses. The table has been corrected.

---

## Notes

1. All claims in the content files now have appropriate scientific citations
2. References sections have been added at the end of each module/deep-dive
3. Both footnote-style and inline citation formats are used depending on context
4. Primary sources (original research papers) were prioritized over secondary sources
5. Most recent guidelines were used (e.g., EWGSOP2 over EWGSOP1, USPSTF 2025 over 2018)
